A high-throughput scintillation proximity assay for sphingosine-1-phosphate lyase

Assay and Drug Development Technologies

Volumn 12, Issue 5, 2014, Pages 293-302

  Kashem, Mohammed A ^a   Wa, Chunling ^b   Wolak, John P ^a   Grafos, Nicholas S ^a   Ryan, Kelli R ^a   Sanville Ross, Mary L ^a   Fogarty, Kylie E ^a   Rybina, Irina V ^b   Shoultz, Alycia ^b   Molinaro, Teresa ^a   Desai, Sudha N ^a   Rajan, Anusha ^a   Huber, John D ^a,b,c   Nelson, Richard M ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b Departments of Biotherapeutics   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYASE; SPHINGOSINE 1 PHOSPHATE LYASE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; RECOMBINANT PROTEIN; SPHINGOSINE 1-PHOSPHATE LYASE (ALDOLASE);

ANIMAL EXPERIMENT; ARTICLE; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SCINTILLATION; SCINTILLATION PROXIMITY ASSAY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOCATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; HUMAN; LYMPHOPENIA; METABOLISM; SCINTILLATION COUNTING; STRUCTURE ACTIVITY RELATION;

ALDEHYDE-LYASES; ANIMALS; BIOCATALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LYMPHOPENIA; MASS SPECTROMETRY; MICE; MOLECULAR STRUCTURE; RECOMBINANT PROTEINS; SCINTILLATION COUNTING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84902474294     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2014.575     Document Type: Article

References (34)

1. Saba JD, Hla T: Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res 2004;94:724-734.
2. Rosen H, Sanna MG, Cahalan SM, Gonzalez-Cabrera PJ: Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends Immunol 2007;28:102-107.
3. Kunkel GT, Maceyka M, Milstien S, Spiegel S: Targeting the sphingosine-1- phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov 2013;12:688-702.
4. Pyne NJ, Tonelli F, Lim KG, Long JS, Edwards J, Pyne S: Sphingosine 1-phosphate signalling in cancer. Biochem Soc Trans 2012;40:94-100.
5. Spiegel S, Milstien S: The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol 2011;11:403-415.
6. Iwasaki T, Tsunemi S, Kitano S, et al.: Role of sphingosine 1-phosphate signaling for the pathogenesis of autoimmune diseases. Inflamm Regen 2011;31:175-183.
7. Spiegel S, Merrill AH Jr: Sphingolipid metabolism and cell growth regulation. FASEB J 1996;10:1388-1397.
8. Hannun YA, Luberto C, Argraves KM: Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry 2001;40:4893-4903.
9. Van Veldhoven PP: Sphingosine-1-phosphate lyase. In: Sphingolipid Metabolism and Cell Signaling Part A. Merrill AH Jr, Hannun YA (eds.), pp. 244-254. Academic Press, New York, 2000.
10. Ikeda M, Kihara A, Igarashi Y: Sphingosine-1-phosphate lyase SPL is an endoplasmic reticulum-resident, integral membrane protein with the pyridoxal 5-phosphate binding domain exposed to the cytosol. Biochem Biophys Res Commun 2004;325:338-343.
11. Van Veldhoven PP, Mannaerts GP: Subcellular localization and membrane topology of sphingosine-1-phosphate lyase in rat liver. J Biol Chem 1991;266: 12502-12507.
12. Serra M, Saba JD: Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv Enzyme Regul 2010; 50:349-362.
13. Borowsky AD, Bandhuvula P, Kumar A, et al.: Sphingosine-1-phosphate lyase expression in embryonic and adult murine tissues. J Lipid Res 2012;53:1920-1931.
14. Bagdanoff JT, Donoviel MS, Nouraldeen A, et al.: Inhibition of sphingosine-1- phosphate lyase for the treatment of autoimmune disorders. J Med Chem 2009;52:3941-3953.
15. Bandhuvula P, Honbo N, Wang G-Y, et al.: S1P lyase: a novel therapeutic target for ischemia-reperfusion injury of the heart. Am J Physiol Heart Circ Physiol 2011;300:H1753-H1761.
16. Bandhuvula P, Saba JD: Sphingosine-1-phosphate lyase in immunity and cancer: silencing the siren. Trends Mol Med 2007;13:210-217.
17. Saba JD, de la Garza-Rodea AS: S1P lyase in skeletal muscle regeneration and satellite cell activation: exposing the hidden lyase. Biochim Biophys Acta 2013; 1831:167-175.
18. Vogel P, Donoviel MS, Read R, et al.: Incomplete inhibition of sphingosine 1- phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions. PLoS One 2009;4:e4112.
19. Billich A, Baumruker T, Beerli C, et al.: Partial deficiency of sphingosine-1-phosphate lyase confers protection in experimental autoimmune encephalomyelitis. PLoS One 2013;8:e59630.
20. Bagdanoff JT, Donoviel MS, Nouraldeen A, et al.: Inhibition of sphingosine 1- phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1- (4-((1R, 2S, 3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2- yl)ethanone oxime (LX2931) and (1R, 2S, 3R)-1-(2-(isoxazol-3-yl)-lH-imidazol-4- yl)butane-1,2,3,4- tetraol (LX 2932). J Med Chem 2010;53:8650-8662.
21. Oskouian B, Sooriyakumaran P, Borowsky AD, et al.: Sphingosine-1- phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is downregulated in colon cancer. Proc Natl Acad Sci USA 2006;103:17384-17389.
22. Bandhuvula P, Fyrst H, Saba JD: A Rapid fluorescent assay for sphingosine-1- phosphate lyase enzyme activity. J Lipid Res 2007;48:2769-2778.
23. Bandhuvula P, Li Z, Bittman R, Saba JD: Sphingosine 1-phosphate lyase enzyme assay using a BODIPY-labeled substrate. Biochem Biophys Res Commun 2009;380:366-370.
24. Berdyshev EV, Goya J, Gorshkova I, et al.: Characterization of sphingosine-1- phosphate lyase activity by electrospray ionization-liquid chromatography/ tandem mass spectrometry quantitation of (2E)-hexadecenal. Anal Biochem 2011;408:12-18.
25. Reina E, Camacho L, Casas J, Van Veldhoven PP, Fabrias G: Determination of sphingosine-1-phosphate lyase activity by gas chromatography coupled to electron impact mass spectrometry. Chem Phys Lipids 2012;165: 225-231.
26. Zhang J-H, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
27. Glickman JF, Schmid A, Ferrand S: Review scintillation proximity assays in highthroughput screening. Assay Drug Dev Technol 2008;6:433-455.
28. Lewis ND, Haxhinasto SA, Anderson SM, et al.: Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of SIP3. J Immunol 2013;190:3533-3540.
29. Brinkmann V, Billich A, Baumruker T, et al.: Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883-897.
30. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer, New York, 2009.
31. R Development Core Team: R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2012.
32. Cook ND: Scintillation proximity assay: a versatile high-throughput screening technology. Drug Disc Today 1996;1:287-294.
33. Bourquin F, Riezman H, Capitani G, Grütter MG: Structure and function of sphingosine-1-phosphate lyase, a key enzyme of sphingolipid metabolism. Structure 2010;18:1054-1065.
34. August EM, Patnaude L, Hopkins J, et al.: Development of a high-throughput assay to measure histidine decarboxylase activity. J Biomol Screen 2006; 11:816-821.